Clinical Trials Logo

Irritable Bowel Syndrome clinical trials

View clinical trials related to Irritable Bowel Syndrome.

Filter by:

NCT ID: NCT06124313 Active, not recruiting - Clinical trials for Irritable Bowel Syndrome

A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health

Start date: September 14, 2023
Phase: N/A
Study type: Interventional

This is a virtual single-group study that will last 12 weeks. Participants will take 1 capsule every day, with water. Questionnaires will be completed at baseline, 2 weeks, 4 weeks, and 12 weeks.

NCT ID: NCT06123234 Recruiting - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Randomised Double-blind Active vs. Placebo Clinical Trial on the Effect of a Food Supplement on IBS-D in Children

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test a food supplement in children of 3-12 years with IBS-D. The main questions it aims to answer are: - Is the tested supplement able to improve and/or reduce IBS-related symptoms? - After administration of the food supplement, how does the state of intestinal inflammation improve? - Is the gut microbiota modified? Participants will take the food supplement every day for 2 months. After 30 days and after 60 days, they will be visited from the gastroenterologist. - They have to fill in the questionnaire and the symptom's diary weekly and deliver it to the gastroenterologist during the visits - At the first visit, they will collect the faecal sample for the analysis of inflammatory markers and gut microbiota - After 30 days, they will collect the faecal sample for the analysis of inflammatory markers - After 60 days, they will collect the faecal sample for the analysis of gut microbiota Researchers will compare with placebo to see if the product is effective.

NCT ID: NCT06117865 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Digital Treatment of Irritable Bowel Syndrome (IBS)

DIGIBS
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The aim of this work is to identify whether the digital treatment program Mage-tarmskolen has an effect on patients with IBS. Our secondary objectives is to address multiple aspects of digital treatmtent success of the different modules. The patients will be randomized to one of four arms and will be delivered different kinds of digital treatment. All patients will have access to ask questions to a registered dietitian. Primary end point is the proportion of patients with treatment success in the low FODMAP, behavioral therapy or both groups, versus the patient education group (sham). Treatment effect is defined as an improvement of 50 points or more on the IBS severity scoring system at 3 months after treatment start compared to the score before treatment.

NCT ID: NCT06104631 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome-like Symptoms

A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

Relieve
Start date: February 2024
Phase: N/A
Study type: Interventional

Crohn's disease is a chronic and complex inflammatory bowel disease affecting the gastrointestinal tract, causing symptoms like abdominal pain, diarrhea, and fatigue. While its exact cause is unclear, it involves genetic, environmental, and immunological factors. Crohn's disease can lead to nutrient deficiencies and has unpredictable flare-ups and remission periods. During the remission phases, irritable bowel syndrome (IBS)-like symptoms can persist in 50% of patients, for which no satisfactory treatment is available yet. Chitin-glucan is prebiotic, obtained by extraction, isolation and purification from a fungal resource: the mycelium of Aspergillus niger (a microscopic fungus of the Ascomycetes family) of which it composes the cell walls. The biopolymer consists essentially of two types of polysaccharide chains: chitin (poly-N-acetyl-D-glucosamine) and beta-(1,3)-D-glucan (D-glucose units linked essentially via beta-1,3 bonds). Because of its beta bond, human intestinal enzymes cannot digest it, as a result, the majority of chitin-glucan can reach the colon where it can be fermented by the microbiota. By modulating the composition and/or activity of the intestinal microbiota, fermentation of chitin-glucan could have beneficial effects on health. The aim of the RELIEVE study is to assess if BK003 could improve the relief of global symptoms, individual symptoms, stool consistency and frequency of evacuations, quality of life, anxiety, and depression in patients with Crohn's disease in remission without treatment or with stable maintenance therapy and having IBS-like symptoms and to confirm the product's safety.

NCT ID: NCT06097598 Not yet recruiting - Faculty of Medicine Clinical Trials

Prevalence of Irritable Bowel Syndrome in Medical Students Africa

Irritablebowel
Start date: October 20, 2023
Phase:
Study type: Observational

The aim of the present study was to assess the prevalence of IBS among medical students in the Middle East and North Africa and to investigate the sociodemographic, lifestyle, and clinical factors associated with IBS. A better understanding of IBS correlates is expected to improve our therapeutic approach to IBS in this population.

NCT ID: NCT06090110 Recruiting - Clinical trials for Irritable Bowel Syndrome

Vagal Nerve Stimulation in Irritable Bowel Syndrome

RESILIENCE
Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are: - To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment. - To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately. - To evaluate the effect of treatment on quality of life - To evaluate the effect of treatment on depression - To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed. In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode. Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.

NCT ID: NCT06066866 Not yet recruiting - Healthy Clinical Trials

Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment

Start date: January 1, 2024
Phase:
Study type: Observational

GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.

NCT ID: NCT06032117 Recruiting - Clinical trials for Irritable Bowel Syndrome

Characterizing Protein Biomarkers of Post-infection Irritable Bowel Syndrome

Start date: April 11, 2024
Phase:
Study type: Observational

The investigators will characterize and compare protein signatures between groups with and without post-infection irritable bowel syndrome (PI-IBS). From previous Healthy Nevada Project (HNP) participants, at least 60 patients with PI-IBS and 60 healthy controls will undergo additional proteomics testing, age, sex and race/ethnicity-matched healthy. The investigators will use proteomic testing to detect, quantify and characterize serum protein biomarkers and protein signatures, and compare biomarkers and signatures between the patient groups of interest. Serum samples will be analyzed by the Nevada Proteomics Center. Samples will first undergo protein digestion, then peptides are separated using liquid chromatography (LC), mass spectral analysis is performed using an Orbitrap Eclipse mass spectrometer (Thermo Scientific, San Jose, CA) using data-independent acquisition (DIA). Library generation and data analysis will be performed using Spectronaut software (Biognosys, Schlieren, Switzerland). The Nevada Proteomics Center and Bioinformatics Center will be engaged during the data analyses comparing biomarkers and signatures between the patient groups of interest. This research aim has the potential to add to our understanding of the underlying mechanisms of PI-IBS and to create reliable differentiating protein biomarkers to better diagnose PI-IBS.

NCT ID: NCT06028035 Completed - Clinical trials for Irritable Bowel Syndrome-bile Acid Diarrhea

A Study of Hemp Hull WFI for IBS Diarrhea

Start date: October 6, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is the effect of a study bar, which contains 15 grams of insoluble dietary fiber total sourced from Hemp hulls, on intestinal permeability in irritable bowel syndrome (IBS)-bile acid diarrhea individuals.

NCT ID: NCT06013410 Recruiting - Clinical trials for Irritable Bowel Syndrome

Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome

IBS
Start date: August 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the pathophysiological effects of the persistently colonized microbiome in irritable bowel syndrome (IBS) patients. The main questions it aims to answer are: Question 1: the microbiome difference of the biofilm between IBS and healthy patients. Question 2: the metabolic product patterns between IBS and healthy patients. Participants will need to take a colonoscopy examination, two gut mucosal biopsy samples will be collected during the examination. Researchers will compare the IBS and healthy control groups to see if there was the disease-specific pattern in the microbiome and metabolic product of the biofilm.